RARE stock news · Ultragenyx Pharmaceutical
Get alerts for RARE
Follow Ultragenyx Pharmaceutical (RARE) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for RAREUltragenyx Pharmaceutical shared its third-quarter results, including FDA approvals for two new treatments.
NeutralUltragenyx won FDA approval for Genglycose and FIUVI and kept its 2026 sales forecast at $730 million to $760 million. Trial setbacks make the news mixed.
Ultragenyx Pharmaceutical says it reached a deal with Navinta to let them sell a generic version of DOJOLVI.
Bad for RAREUltragenyx settled a patent case by allowing Navinta to sell a generic version of DOJOLVI starting in 2033 without royalties. That creates future competition, so the news weighs against the company.
Ultragenyx Pharmaceutical Inc. has agreed to sell a special voucher for $210 million.
Good for RAREUltragenyx agreed to sell its FDA-awarded voucher for $210 million in cash at closing. The sale favors the company, though NIH receives a share and closing conditions remain.
Thursday's intraday session sees significant fluctuations in 12 health care stocks.
Bad for RAREA large 44.3% intraday drop is a significant negative development for the company in the session.
Following unsatisfactory Phase 3 trial outcomes, Ultragenyx is compelled to implement cost reductions.
Bad for RAREUltragenyx Pharmaceutical Inc. shares fell 47.57% in premarket trading after the company announced that its Phase 3 trial for the apazunersen therapy for Angelman syndrome failed to meet its primary and secondary endpoints, prompting a strategic review and significant cost reductions.
Will CrowdStrike Surge Beyond 15%? Discover 10 Leading Analyst Predictions for Thursday.
Bad for RAREHC Wainwright substantially cut Ultragenyx’s price target despite maintaining a Buy rating, signaling a materially weaker outlook.
Snowflake Inc's stock jumps more than 24% in pre-market trading; 20 other stocks also showing movement.
Bad for RAREFailure of a Phase 3 study on key endpoints is a major negative for clinical prospects and valuation.
FDA grants approval to Ultragenyx for its inaugural gene therapy.
NeutralUltragenyx Pharmaceutical Inc. received FDA accelerated approval for its gene therapy Genglycos, the first treatment for Glycogen Storage Disease Type Ia. This approval is expected to drive significant revenue growth due to the high cost of treatment, positively impacting the company's stock in the immediate term.